Moderate

Parkinson's disease motor complications and advanced therapies

Fluctuations, dyskinesia and device therapy · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Management of wearing-off, on-off fluctuations and levodopa-induced dyskinesia in established Parkinson's disease, and escalation to device-assisted therapies when oral medication fails. Aims to smooth motor response and preserve quality of life.

Red flags

  • Impulse control disorder (gambling, hypersexuality) on dopamine agonists
  • Hallucinations or psychosis
  • Severe freezing with falls
  • Dopamine agonist withdrawal syndrome
  • Sudden off periods with immobility and aspiration risk

Assessment

Differential diagnosis

  • Disease progression versus suboptimal dosing
  • Non-motor fluctuations
  • Dopamine dysregulation syndrome
  • Peak-dose versus diphasic dyskinesia
  • Psychogenic movements
  • Medication malabsorption (gastroparesis)

Investigations

  • Detailed motor diary mapping on/off time and dyskinesia
  • Medication timing and dietary protein review
  • Assess for gastroparesis affecting absorption
  • Cognitive and psychiatric screen before device therapy
  • MRI brain for DBS planning
  • Review non-motor symptoms (mood, sleep, autonomic)

Management

  • Map the pattern of fluctuations and dyskinesia with a timed diary
  • Optimise oral levodopa: shorten dosing intervals and consider taking before meals
  • Add a COMT inhibitor or MAO-B inhibitor to extend levodopa effect
  • Add or adjust a dopamine agonist, balancing against impulse control risk
  • Use amantadine to suppress troublesome dyskinesia
  • Treat peak-dose dyskinesia by reducing individual levodopa doses and increasing frequency
  • Screen for impulse control disorders at every review
  • Refer for device-assisted therapy when oral optimisation fails: deep brain stimulation, apomorphine infusion or intestinal levodopa gel
  • Address non-motor fluctuations and comorbidities
  • Involve specialist Parkinson's nurse and multidisciplinary team

Drugs & doses

Levodopa/carbidopa dose fractionation (smaller, more frequent doses)
Entacapone 200 mg PO with each levodopa dose (COMT inhibitor)
Rasagiline 1 mg PO daily or safinamide 50-100 mg PO daily (MAO-B inhibitor)
Amantadine 100 mg PO BD-TDS for dyskinesia
Apomorphine subcutaneous: intermittent 2-6 mg rescue or continuous infusion
Levodopa-carbidopa intestinal gel via PEG-J
Opicapone 50 mg PO daily as alternative COMT inhibitor

Disposition

Specialist movement disorder clinic. Refer to tertiary centre for DBS or infusion therapies. Parkinson's specialist nurse support.

Complications & pitfalls

  • Disabling dyskinesia
  • Impulse control disorders
  • Dopamine dysregulation syndrome
  • Psychosis and cognitive decline
  • Device-related complications (infection, hardware, stoma issues)

Exam pearls

  • Smaller, more frequent levodopa doses smooth wearing-off; amantadine targets dyskinesia
  • Always screen for impulse control disorders with dopamine agonists
  • Never stop dopaminergic therapy abruptly (risk of akinetic crisis/NMS-like syndrome)
  • Refer for device therapy before patients become too frail or cognitively impaired to benefit

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.